Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Society of Chinese Bioscientists in America Name of Member________________________________ 2015 ELECTION BALLOT OFFICE NOMINEES 1. PRESIDENT: (VOTE FOR 1) (Jan. 1, 2018 - Dec. 31, 2019) 2. SECRETARY: (VOTE FOR 1) (Jan. 1, 2018 - Dec. 31, 2019) 3. TREASURER: (VOTE FOR 1) (Jan. 1, 2018 - Dec. 31, 2019) 4. COUNCILOR: (VOTE FOR 2) (Jan. 1, 2016 - Dec. 31, 2019) 5. NOMINATION: (VOTE FOR 6) (Jan. 1, 2016 - Dec. 31, 2017) 6. MEMBERSHIP: (VOTE FOR 6) (Jan. 1, 2016 - Dec. 31, 2017) VOTE (√) Pu Paul Liu (NHGRI, Nat. Institutes of Health) _____ Lin Mei (Georgia Regents university) _____ Jianming Xu (Baylor College of Medicine) _____ Bing Gao (NIAAA, Nat. Institutes of Health) _____ Fen Wang (Texas A&M Health Sci. Center) _____ Pan Zheng (Children’s National Medical Center) _____ Keji Zhao (NHLBI, Nat. Institutes of Health) _____ Mien-Chie Hung (MD Anderson Cancer Center) _____ Yimin Zou (University of California, San Diego) _____ Min Han (Univ. of Colorado, Boulder) _____ Paul J. Chiao (University of Texas, Houston) _____ Yingzi Yang (Harvard University) _____ Huilin Zhou (University of California, San Diego) _____ Qi-Jing Li (Duke University) _____ Wanjun Chen (NIDCR, Nat. Institutes of Health) _____ Julian J.-L. Chen (Arizona State University) _____ Xin Wei Wang (NCI, Nat. Institutes of Health) _____ Yi Li (Baylor College of Medicine) _____ Xuhang Li (Johns Hopkins University) _____ Wei Gu (Columbia University) _____ Zhibin Chen (University of Miami) _____ Yingming Zhao (University of Chicago) _____ Deyu Fang (Northwestern University) _____ Yixian Zheng (Carnegie Institution of Science) _____ Yue Xiong (University of North Carolina) _____ You must type or sign your name on this ballot for your votes to be counted. All votes will be kept strictly confidential. Please return your signed BALLOT by June 1, 2015 via e-mail attachment to the SCBA Co-Executive Director, Chris Lau: [email protected] and The SCBA Treasurer, Hui Zheng: [email protected] Candidates for President 1. PRESIDENT: (VOTE FOR 1) Pu Paul Liu (NHGRI, Nat. Institutes of Health) _____ (Jan. 1, 2018 -‐ Dec. 31, 2019) Lin Mei (Georgia Regents university) _____ Pu Paul Liu, MD, Ph.D. Current Positions: Deputy Scientific Director Senior Investigator (tenured) National Human Genome Research Institute (NHGRI), NIH Education and training: MD, Capital Medical University, Beijing, China, 1982 Ph.D., Genetics, University of Texas, GSBS at Houston, 1991 Postdoctoral fellow, HHMI and University of Michigan, 1992-1993 Previous Positions: 1993 – 1995 1995 - 2001 2006 Senior Staff Fellow, National Center for Human Genome Research, NIH Tenure-Track Investigator, National Center for Human Genome Research, NIH Acting Chief, Genetics and Molecular Biology Branch, NHGRI Research Interests: My laboratory investigates the molecular mechanisms of leukemia, a collection of diseases that strikes approximately 43,000 Americans each year. We focus our attention on two transcription factors, RUNX1 and CBF, which play major roles in human leukemia pathogenesis. These two proteins also play critical roles at multiple stages of hematopoiesis. Understanding their roles during hematopoiesis will enhance our understanding of their involvement in leukemogenesis, as well as their roles in related hematologic diseases such as familial platelet disorder, in which RUNX1 is mutated. Significantly, I cloned the breakpoints of chromosome 16 inversion, a common chromosome abnormality in human acute myeloid leukemia, and identified the molecular consequence of the inversion as the generation of a fusion gene, CBFB-MYH11. My lab has been the leader for the study of this fusion gene in the past 20 years. We use genetic and genomic approaches, as well as mouse and zebrafish models, for our research. We carry out chemical library screens and we recently started using human iPS cells for our investigations as well. Our long-term goal is to translate our findings to improved clinical practices including better diagnosis and treatment of leukemia and other related hematologic diseases. Previous services to SCBA: 2009 President, Baltimore-Washington Chapter, 2009 2011 Organizing Committee, 13th SCBA International Symposium, Guangzhou, China 2011Editorial Board Member, Cell & Bioscience 2014-2017 Council Member Selected Honors and Awards, and non-SCBA services: 1994 – 1997 Leukemia Society of America Special Fellow 1999 Election to the American Society for Clinical Investigation 2002 John H. Blaffer Lecture, MD Anderson Cancer Center, Houston, TX 2002, 2007, 2009 NIH Merit Award 2004 Election to Association of American Physicians 2007 NIH Asian and Pacific Islander Organization Scientific Achievement Award 2010 NIH Director’s Award 2008-2013 Member, American Cancer Society LIB peer review committee Member, Scientific Committee on Myeloid Biology, American Society of 2011-2017 Hematology 2006Chair, NHGRI Promotion & Tenure Committee 2008Senior Advisor to Deputy Director for Intramural Research, NIH 2011Chair, NHGIR IC Standing Committee 2013-2015 Co-Chair, NIH Earl Stadtman Investigator Search Executive Committee 2014-2017 Editorial Board Member, Blood 1 Page 1 of 1 Lin Mei Current Positions: Professor and Chair, Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Georgia Regents University Education: Diploma of Medicine, 1982, Jiangxi Medical College (now Nanchang University), China MS (Neuropharmacology), 1985, Institute of Pharmacology & Toxicology, Beijing, China. PhD (Pharmacology and Toxicology), 1989, University of Arizona. Postdoctoral Fellow, Department of Neuroscience, Johns Hopkins University, School of Medicine. Appointments: 1994-1999, Assistant Professor, Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 1999-2002, Assistant Professor; 2002-2004 Associate Professor, Neurobiology, Pathology, and Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama 2004-present, Professor of Neurology; 2009-2014, Director of Institute of Molecular Medicine and Genetics; 2014-present, Professor and Chair (Inaugural), Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Georgia Regents University, Augusta, Georgia Research Interest: My laboratory is interested in synapse formation and function. Our research contributes to a better understanding of pathophysiological mechanisms of muscular dystrophy and brain disorders including schizophrenia. Past Service to SCBA: Life-time member (since 2004; member since 1994). 2009, Co-Chair, Program Committee of 2009 SCBA International Symposium, Taipei. 2011, Session Chair, 13th SCBA International Symposium, Guangzhou, China. 2014 – present, Associate Editor, Cell & Bioscience. Selected Honors: 1987, Honorary Citizen of Tucson, the City of Tucson, Arizona; 2004, Outstanding Young Investigator Award (Type B), National Natural Science Foundation, China; 2004, Georgia Research Alliance Eminent Scholar in Neuroscience; 2005, Chung Kong (Chang Jiang) Scholar, Li Ka Shing Foundation of Hong Kong and Ministry of Education, China; 2008, Mathilde Solowey Lecture Award in Neurosciences, Foundation for Advanced Education in Sciences at NIH; 2008, Distinguished Investigator, National Alliance for Research on Schizophrenia and Depression (NARSAD); 2009, Alberta Heritage Foundation for Medical Research Visiting Lecturer; 2011, Thousand Talents Scholar (Type B), Central Coordination Committee on the Recruitment of Talents Project, China; 2014, Fellow, American Association for the Advancement of Science (AAAS) -1- Candidates for Secretary 2. SECRETARY: (VOTE FOR 1) Jianming Xu (Baylor College of Medicine) _____ (Jan. 1, 2018 -‐ Dec. 31, 2019) Bing Gao (NIAAA, Nat. Institutes of Health) _____ JIANMING XU, Ph.D. Current Positions: Professor with Tenure Department of Molecular and Cellular Biology and Dan Duncan Cancer Center Baylor College of Medicine Education and Training: B.S., China West Normal University, China 1982 M.S., Beijing Normal University, China 1985 Ph.D., Clarkson University, NY, USA 1994 Postdoctoral fellow, IBT, Texas A&M University Health Science Center, TX, USA 1993-1994 Postdoctoral fellow, Baylor College of Medicine, TX, USA 1994-1997 Previous Positions: 1997-1999 Instructor, Department of Molecular and Cellular Biology (MCB), Baylor College of Medicine (BCM) 1999-2005 Assistant Professor, Department of MCB, BCM 2005-2010 Associate Professor, Department of MCB, BCM 2010-present Professor, Department of MCB and Dan Duncan Cancer Center, BCM Research Interest: My laboratory has a longstanding interest in steroid hormone regulated gene expression and steroid hormone promoted cancers including breast, prostate and endometrial cancers. We were the first to use genetically manipulated mouse models to define the genetic roles of the initially identified several nuclear receptor coregulators including SRC-1, SRC-3 (AIB1) and NCOA6 (AIB3) in development, steroidregulated organ function and steroid-promoted cancers. We continue investigating the molecular mechanisms responsible for transcriptional coregulators to promote or inhibit steroid-promoted carcinogenesis and trying to identify molecular inhibitors of these coregulators for inhibiting cancer cell growth and metastasis. Past Services to SCBA: • A member of SCBA Nomination Committee, 1/2012 – 12/2013. • Life-time member of SCBA 2004 • The Treasure of SCBA TX Chapter, 2005 – 2006 • The President Elect of SCBA TX Chapter, 2009 – 2010 • The President of SCBA TX Chapter, 2010 – 2011 • As one of the four committee members, Co-organized the SCBA-TX Annual Symposium, 4/29/2006, Houston, TX, ~200 attendees. • As one of the four committee members, Co-organized the 2009 SCBA-TX Annual Symposium, 4/25/2010, Houston, TX, ~200 attendees. • As one of the four committee members, Co-organized the 2010 SCBA-TX Annual Symposium, 5/1/2010, Houston, TX, ~200 attendees. • The Chairperson of the Organization Committee, organized the Texas-Sichuan International Biomedical Research Symposium on behalf of SCBA-TX, Chengdu 2010. Chengdu, China, 10/2410/27/2010. (There were 45 speakers with 26 from USA and about 250 audiences. The scientific program includes three plenary sections, and a total of 8 concurrent sessions with 2 at a time. I was • • • • • • responsible for setting up the entire program and inviting all the speakers. I also represented SCBATX to give a speech in the Opening Ceremony in addition to a research lecture, and to coordinate all the meeting business with our local host, Luzhou Medical College.) The Chairman of the Organization Committee, SCBA-TX 2011 Annual Meeting, Houston, TX, 4-232011 at Baylor College of Medicine. Chaired the entire one day meeting: a morning symposium with six speakers; an election and financial report section; a trainee presentation section with six separate groups; a keynote speaker section; and an award ceremony and closing section. About a total of 200 attendees. Member of the Organizing Committee, 2011 SCBA International Symposium. Served as the Session Co-chair for: Breast Cancer, Stem Cells and Metastasis. Guangzhou, China, Aug. 25-29, 2011. Member of the Organizing Committee, The Second Biennial International Symposium of the SCBATX Chapter: Jiangsu-Texas Biomedical Symposium. Frontier on Cancer and Other Human DiseasesFrom Mechanisms to Bedside. Sept. 14-18, 2012, Nanjing, China. About 400 people attended this meeting. Co-Chair with Dr. Sophia Tsai to run the session of “Prostate Cancer Perspectives”, The 14th SCBA International Symposium, Xi-An, China, July 18-22, 2013. Co-Chair with Dr. Yi Li to run the session of “Breast Cancer Development”, The 14th SCBA International Symposium, Xi-An, China, July 18-22, 2013. Member of the Organizing Committee: China-US Biomedical Symposium, co-organized by the Society of Chinese Bioscientists in America Texas Chapter and the Fourth Affiliated Hospital of Hebei Medical University. Shi Jia Zhuang, China, Oct. 18-20, 2014 Selected Achievements, Honors and Awards: • 140 publications related to the research fields of growth factor receptors, nuclear hormone receptors, transcriptional coregulators, embryonic development, reproductive biology, breast cancer and prostate cancer. • Mentored 10 graduate students for PhD and trained 33 postdoctoral fellows. • 82 invited research lectures or presentations. • Journal editorial boards: Journal of Biological Chemistry, 7/2010 –9/2015; International Journal of Biological Sciences, 4/2006–present; The Open Breast Cancer Journal, 2/2009present; Acta Academiae Medicinae Militaris Tertiae, 2008–present; Cell & Bioscience, 2011– present. • Professor Alexander Yeu-Ming Wang Memorial Research Award from SCBA-TX, 4/1998. • Quest Diagnostics Young Investigator Award from the Endocrine Society, 6/1998. • Endocrine Society Travel Grant Award, 6/2001. • Breast Cancer Research Career Award from the US Department of Defense, 4/2000. • Mellon Foundation Young Investigator Research Award, 4/2002. • The Cancer Research Award, 1/2005, The Charlotte Geyer Foundation. • The Research Scholar Award, 1/2005, The American Cancer Society. • 2008 Research Medal Award, Department of MCB, BCM. • The Era of Hope 2005 – Department of Defense Breast Cancer Research Program Meeting Travel Award, 6/8/2005. BIN GAO, MD., PhD Current Position: Chief, Laboratory of Liver Diseases NIAAA, NIH Education and training: MD.: Wannan Medical College, China 1986 PhD: Norman Bethune Medical University, 1991 Postdoctoral Fellow: 1991-1992: NIH; 1992-1995: Medical College of Virginia Previous Positions: 1995-2000: Assistant Professor, Department of Pharmacology/Toxicology, Medical College of Virginia 2000-2005: Tenure track investigator, Chief, Section on Liver Biology, NIAAA, NIH 2005-2009: Senior Investigator, Chief, Section on Liver Biology, NIAAA, NIH 2009-present: Senior Investigator, Chief, Laboratory of Liver Diseases, NIAAA, NIH Research Interest: Immunological aspects and molecular pathogenesis of liver diseases Hepatic inflammation and immunity in liver diseases Novel therapeutic targets of alcoholic and nonalcoholic liver diseases Past service to SCBA: 2010-2011: President, SCBA DC-Baltimore chapter 2011: Organizer and Chair: SCBA local chapter and NIAAA joint symposium on Digestive Diseases, NIH 2011: session organizer and chair: Stem cell symposium at the Annual CBA meeting, MD 2011: session organizer and chair, The 13th SCBA International Conference, Guangzhou 2015-16: SCBA nomination committee 2015: session chair, the first SCBA DC-Baltimore chapter symposium Selected Honors and Awards: 1991: Forgarty International Visiting Fellow Award, NIAAA, NIH 2000: International Society for Biomedical Research on Alcoholism (ISBRA) Junior Investigator Award 2002: Elected to the American Society for Clinical Investigation (ASCI) Member 2008: Named as the member of Senior Biomedical Research Service (SBRS) by NIH director 2010: NIH Asian & Pacific Islander American Organization (APAO) award Candidates for Treasurer 3. TREASURER: (VOTE FOR 1) Fen Wang (Texas A&M Health Sci. Center) (Jan. 1, 2018 -‐ Dec. 31, 2019) Pan Zheng (Children’s National Medical Center) _____ _____ FEN WANG, Ph.D. Current Positions: Professor and Director, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center Education and Training: B.S., Microbiology, Xiamen University, 1982, Xiamen, China M. S., Cell Biology, Xiamen University, 1985, Xiamen, China Ph. D., Biochemistry/Cell Biology, Clarkson University, 1994 Potsdam, NY Postdoctoral Fellow, Texas A&M University, Houston, TX 1994-1996 Previous Positions: 1996-1999 Assistant Research Scientist, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas 2000-2006 Assistant Professor, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas 2006-2010 Associate Professor with tenure, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas 2010-Present Professor, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas Research Interests: The laboratory focuses on understanding the molecular basis of cell signaling, and how aberrant cell signaling leads to birth defects and causes cancers. Using in vitro cell culture systems and in vivo mouse models, we study how the fibroblast growth factor (FGF) activates its receptor (FGFR) tyrosine kinase, and how the activated FGFR transmits the signals to downstream targets and regulates proliferation, differentiation, homeostasis, and function of the cells, as well as in organogenesis and development, including prostate and cardiovascular system development. The laboratory also employs molecular biology, cell biology, and mouse genetic technologies to study how aberrant FGF signals promote tumor initiation, progression, and metastasis. In addition, how environmental factors contribute to tumorigenesis and congenital birth defects by modulating FGF signal intensity and specificity is also under the scope of our research interests. Past Service to SCBA: • Life-time member of SCBA 2003 • The Treasure of SCBA TX Chapter, 2003 – 2004 • The Secretary of SCBA TX Chapter, 2004 – 2005 • The President Elect of SCBA TX Chapter, 2006 – 2007 • The President of SCBA TX Chapter, 2007 – 2008 • Organizing Committee, Annual Symposium, Society of Chinese Bioscientists in America, Texas Chapter, 2006 • Organizing Committee, Annual Symposium, Society of Chinese Bioscientists in America, Texas Chapter, 2007 Selected Honors and Awards, and non-SCBA Service • 2015President, Xiamen University America Alumni Association, • 2014President, Dr. Deyao Wang and Wenzheng Wang Scholarship Foundation, Pan Zheng, MD, PhD Current Position: Senior Investigator and McKnew Professor of Cancer Biology Center for Cancer and Immunology Research Children’s National Medical Center, Washington, DC Education and training: MD, Peking Union Medical College, Beijing, China, 1979 – 1987. Resident, Internal Medicine, PUMC Hospital, Beijing, China, 1987 – 1989. PhD, Immunobiology, Yale University, New Haven, CT, 1994. Resident, Pathology, New York University, NY, 1994 - 1998. Previous Positions: 1998 – 2003: Assistant Professor, Dept of Pathology, The Ohio State University School of Medicine. 2003 – 2006: Associate Professor, Dept of Pathology, The Ohio State University School of Medicine. 2006 – 2011: Associate Professor, Dept of Surgery and Pathology, University of Michigan School of Medicine. 2011 – 2013: Professor, Dept of Surgery and Pathology, University of Michigan School of Medicine. Research Interest: My research interests are tumor immunology, cancer biology and signal transduction in hematopoietic stem cells. One of our major efforts is in study TSC-mTOR signaling in rejuvenation of hematopoietic stem cells (HSC) and immunity. Using genetically modified mice with conditionally deletion of hematopoietic lineage cells, we demonstrated that mTOR inhibition is critical to maintain hematopoietic stem cell quiescence. Activation of mTOR in HSC increased mitochondrial biogenesis and elevated levels of reactive oxygen species (ROS). Short-term rapamycin treatment greatly enhanced the efficacy of influenza vaccination in aged mice. Past services to SCBA Attended SCBA meetings and gave talks in 1998, 2004 and 2009. Selected Honors and Awards, and non-SCBA services 2006 American Cancer Society Research Scholar 2011 – 2013 CBIS, Secretary. 2014 – 2016 CBIS, Board member. Candidates for the Council 4. COUNCILOR: (VOTE FOR 2) Keji Zhao (NHLBI, Nat. Institutes of Health) (Jan. 1, 2016 -‐ Dec. 31, 2019) Mien-‐Chie Hung (MD Anderson Cancer Center) _____ Yimin Zou (University of California, San Diego) _____ Min Han (Univ. of Colorado, Boulder) _____ _____ Keji Zhao, Ph.D. Current Position: Senior Investigator and Director Systems Biology Center National Heart, Lung and Blood Institute, NIH Education and Training Diploma, Changwei Normal College, China, 1980 M.Sc. in Organic Chemistry, Northeast Normal University, China, 1985 Ph.D. in Molecular Biology, University of Geneva, Switzerland, 1996 Postdoctoral Fellow, Stanford University, California, 1996-1999 Previous Positions: 1999 – 2006 2007 – 2011 2011 – present Tenure-Track Investigator, Center of Immunology, National Heart, Lung and Blood Institute, NIH, Bethesda, MD Senor Investigator, Center of Immunology, NHLBI, NIH Senior Investigator and Director, Systems Biology Center, NHLBI, NIH Research Interest: The research in my laboratory focuses on the epigenetic and epigenomic regulation of cell differentiation and cell memory. My laboratory developed the ChIP-Seq and MNaseSeq techniques and also developed corresponding algorithms to analyze these data. We applied these techniques to genome-wide mapping of histone modifications, nucleosome occupancy, and binding profiles of histone modification enzymes and transcription factors. Past services to SCBA: 2011 President-elect, SCBA Washington DC-Baltimore Local Chapter 2012 President, SCBA Washington DC-Baltimore Local Chapter 2011 to present Editorial Board of Cell & Bioscience 2009 Co-organizer of a session of 2009 SCBA Biannual Meeting 2013 member, meeting program committee of 2013 SCBA Biannual Meeting 2013 to 2015 member, SCBA Membership Committee Selected Honors and Awards: 2007 2007 2008 2008 2011 2012 National Institutes of Health Merit Award for “Innovative contributions that have provided novel insights into epigenetic control of gene expression” Appointed to the Senior Biomedical Research Service APAO Award for Significant Accomplishments in Biomedical Research at NIH National Institutes of Health Merit Award NIH Director’s Award Election to AAAS Fellows Program Director/Principal Investigator (Last, First, Middle): BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE MIEN-CHIE HUNG PROFESSOR AND CHAIR eRA COMMONS USER NAME (credential, e.g., agency login) [email protected] EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) DEGREE INSTITUTION AND LOCATION MM/YY FIELD OF STUDY (if applicable) NATIONAL TAIWAN UNIVERSITY, TAIWAN NATIONAL TAIWAN UNIVERSITY, TAIWAN BRANDEIS UNIVERSITY, MASSACHUSETTS WHITEHEAD INSTITUTE, MIT, MASS. B.S M.S. PH.D. POSTDOC 07/73 07/77 05/83 08/86 CHEMISTRY BIOCHEMISTRY BIOCHEMISTRY ONCOGENE Personal Statement I am a Principal Investigator for a P01, an R01, a Susan G. Komen grant, a CPRIT and a co-Project Leader for the Ovarian Cancer SPORE. I also serve as Program Leader of Cell Biology and Signal Transduction Program, Core Director of ShRNA and ORFeome Core Facility and Associate Director of Basic Science Programs of Cancer Center Supporting Grant. Currently, my group’s research focuses on three themes in cancer research: 1) discovery of novel functionality of epidermal growth factor receptor (EGFR) family which might provide useful insight to understand cancer formation and development, 2) identification of crosstalks of signal pathways/networks in cancer cells and tumor microenvironment which could potentially predict resistance to target therapy, and 3) development of marker-guided targeted therapy which will effectively treat cancer patients. Positions and Honors Professional Experience: 1986-1991 Assistant Professor, Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center 09/91-08/94 Associate Professor, Department of Tumor Biology, The University of Texas MD Anderson Cancer Center 09/94Professor, The University of Texas M.D. Anderson Cancer Center 5/99-02/00 Hubert L. and Olive Stringer Distinguished Professorship in Cancer Research, U.T. MD Anderson Cancer Center 03/00-12/02 Ruth Legett Jones Chair, Department of Molecular and Cellular Oncology, U.T MD Anderson Cancer Center 01/03Ruth Legett Jones Distinguished Chair 03/00Chair, Department of Molecular and Cellular Oncology, U. T. MD Anderson Cancer Center 09/08Director, Center for Biological Pathways, U. T. MD Anderson Cancer Center 03/10Vice President for Basic Research, U.T. MD Anderson Cancer Center 07/13Associate Director, Basic Science Programs, CCSG, U.T. MD Anderson Cancer Center 0925-0001/0002 (Rev. 08/12) Page Biographical Sketch Format Page Program Director/Principal Investigator (Last, First, Middle): Honors and Awards: 1989-90 John P. McGovern Outstanding Teacher Award U.T. H.S.C. -Houston (1992-93, 1998-99), 1993 Faculty Achievement Award in Education (1993) and in Basic Research (1998), UTMDACC 1996 Member, Pathology B Study Section (1996 – 2000) and Sub-committee C (2001-2005), NIH. Editorial Board, Clinical Cancer Research (1999–), Cancer Cell (2001-) and Cancer Research (2002-). 2002 Academician of the Academia Sinica, Taiwan 2006 Member, The University of Texas Academy of Health Science Education. 2007 Distinguished Teaching Professor, The University of Texas M. D. Anderson Cancer Center. 2010-16 Full Member, Scientific Advisory Council, Susan G Komen. 2010 Fellow, section of Biological Sciences, American Association for the Advancement of Science. Selected Services/Activities to SCBA: • Vice-President, Houston Chapter - Society of Chinese Bioscientists in America, 1988-1989. • President, Houston Chapter - Society of Chinese Bioscientists in America, 1989-1990. • Session Chairman, Houston Chapter, Third Annual Symposium, Houston, TX, 12/1989 • Session Co-Chairman Fourth International Symposium & Workshop, Singapore, Singapore, 6/1992 • Session Co-Chairman Fifth International Symposium & Workshop, Washington, DC, 6/1993 • Session Chair, Biotechnology Section, Galveston, TX , 4/1998 • Session Chair, Frontier of Biotechnology and Biomedical Science in the New Millennium, The 9th SCBA International Symposium, Taipei, Taiwan, 8/6/2001 • President (international), 1/2004−12/2005 • Member, International Advisory Committee 10th SCBA International Symposium, Beijing, China, 6/2004 • Session Co-Chair, Session: Gene Therapy for cancer, The 10th SCBA International Symposium, Beijing, China, 7/2004 & The 11th SCBA International Symposium, San Francisco, CA, 7/2006 • Co-Chair, The 11th SCBA International Symposium, San Francisco, CA, 7/2006 • Faculty Club, TX Chapter, “A Novel Pathway Linking Cancer, Obesity and Diabetes; and Development of Targeted Cancer Gene Therapy”, Houston, TX, December 14, 2007. • Achievement Award and the Acceptance Speech, "To believe or not to believe: Trafficking of Membrane Tyrosine Kinase Receptors to the nucleus-mechanism, function and clinical implication", 2008 SCBA TX Chapter Symposium, Houston, TX, April 19, 2008. • Co-Chair, Scientific Program Session Chair on Cancer Biology Workshop, 12th SCBA International Symposium, Taipei, Taiwan, 6/2009 • Session Co-Chair, Session: Cancer Etiology: Inflammation, Virology, and Cancer; and Session: Cancer Biomarkers and Experimental Therapeutics, 13th SCBA International Symposium, Guangzhou, China, 7/2011. • SCBA Presidential Award, July 2011. • Keynote Speaker, Cross talk signaling pathways to predict drug resistance: pave a way to develop personalized cancer therapy, Biennial SCBA Texas Chapter China Symposium, Nanjing, China, 9/2012 • Session speaker and co-Chair, Session: New Frontier in Cancer Metastasis, Chair: Dihua Yu, 14th SCBA Biennial Meeting, Xi’An, China, July 18-22, 2013. • Member, Planning Committee, 2014 TX Chapter Annual Meeting • Chair, Scientific Program, 2015 SCBA Biennial Symposium, Taipei, Taiwan, June 26-29, 2015 0925-0001/0002 (Rev. 08/12) Page Biographical Sketch Format Page YIMIN ZOU, Ph. D. Current Positions Professor and Chair Neurobiology Section Biological Sciences Division University of California, San Diego Education and Training B.S., Genetics, Fudan University, China 1988 Ph.D., Biochemistry and Molecular Biology, University of California, San Diego and Davis, 1995 Postdoctoral Fellow, Developmental Neuroscience, University of California, San Francisco, 2000 Previous Positions 2000-2006 Assistant Professor, Department of Neurobiology, the University of Chicago 2006-2006 Associate Professor (with tenure), Department of Neurobiology, the Univesity of Chicago 2006-2011 Associate Professor, Neurobiology Section, University of California, San Diego 2011-present Professor, Neurobiology Section, University of California, San Diego 2012-2014 Vice Chair, Neurobiology Section, University of California, San Diego 2014-present Chair, Neurobiology Section, University of California, San Diego Research Interest My lab studies molecular and cellular mechanisms of axon guidance, synapse formation, and assembly, stability and regeneration of neural circuits. We identify molecular guidance cues that provide directional information for axon wiring in vivo as well as signal transduction pathways and cell biological mechanisms underlying growth cone turning. We also study synaptogenesis and how specific synaptic connection patterns emerge from the interplay of molecular guidance system and neural activity. We are interested in how central nervous system responds to traumatic injury and develop therapeutic approaches to promote axonal and neuronal survival to combat degenerative disorders and improve axon regeneration and functional recovery following spinal cord injury. Selected Honors and Awards, and non-SCBA Services 1989-1993 1993-1995 1995-1996 1996-1998 1999-2000 2002-2005 2002-2004 2003-2005 2003 2005 2006 2006 2008 2009 2011 2011 2012 2012 2013 2013- 2013 2013-2016 2014 2015 2016 2017 CUSBEA Fellowship Institutional Predoctoral NRSA, NIH Institutional Postdoctoral NRSA, NIH Individual Postdoctoral NRSA, NIH Postdoctoral Fellowship from the Spinal Cord Research Foundation Schweppe Foundation Career Development Award March of Dimes Basil O’Connor Starting Scholar Research Award Alfred P. Sloan Research Fellow Award W. M. Keck Foundation Research Achievement Award (Semi-finalist in Keck Young Scholar Competition) Chair of “Minisymposium on Wnt Signaling in Neural Circuit Development” at Society for Neuroscience Meeting. Washington, DC. Gail Beach Memorial Seminar Series at the University of Miami Miller School of Medicine. Miami, Florida Keynote Speaker at Midwest Student Biomedical Research Forum. Omaha, Nebraska. Chair of “Symposium on Genetic determinants specifying neuronal connections” at Society for Neuroscience Meeting. Washington, DC. Killam Research Seminar the Montreal Neurological Institute McGill University. Montreal, Canada. Chair of Symposium Organizer: Signaling and cell biological mechanisms of growth cone guidance at 8th IBRO World Congress of Neurosciences. Florence Italy Organizer of Cold Spring Harbor Asia Meeting on Neural Circuits. Suzhou China S. T. Huang-Chan Memorial Lecture Hong Kong University, Hong Kong, China 北京生科院精品讲座 Organizer of Cold Spring Harbor Asia Meeting on Neural Circuits. Suzhou China Member and Secretary of Board of Directors of Ray Wu Memorial Fund and CBIS Director’s Seminar Series (贝时璋讲座) Institute of Biophysics, CAS Honorary Professor of the University of Hong Kong Dean’s Seminar Series (院长讲座)Peking University Medical School AbCam Meeting on Frontiers of Signaling. Shanghai, China. Co-Organizer of Cold Spring Harbor Asia Meeting on Neural Circuits. Suzhou China Co-Organizer of Keystone Symposium on Neural Circuits, Colorado MIN HAN, Ph.D. Current Position: Investigator of Howard Hughes Medical Institute Professor, Dept of MCDB, Univ. of Colorado at Boulder Member of Cancer Center, Univ. of Colorado at Denver Adjunct Professor and co-director, IDM, Fudan Univ. Education B.S., Biochemistry, Peking (Beijing) University, 1982 Ph.D., Molecular Biology Institute, UCLA 1988 Postdoctoral fellow, Caltech, 1988-1991 Research Accomplishments and Interests My lab has been dynamic in selecting and addressing diverse biological problems, primarily using C. elegans and mouse as model organisms. In the 1990s, we employed several genetic suppressor screens to identify >12 highly conserved regulators of the RTK/Ras/MPK signaling pathway. Our later analysis of nuclear positioning in the worm defined the SUN and KASH nuclear-envelope protein families, as well as the concept of SUN-KASH universal pairing, followed by the functional analyses of the complex in mouse. We were the first to report GW182 as an essential competent of miRISCs and pioneered the application of the miRISC-IP approach to systematically analyze miRNA-target interaction networks under various physiological conditions. We also took systematic approaches to tackle the problem of “genetic redundancy” that masked the roles of many regulators, including tumor suppressors and miRNAs in development. In the last 10+ years, we turned our attention to understanding the functional consequence of fatty acid/lipid variations. Our efforts led to the discoveries of the striking impact of specific lipid metabolism events on several signaling pathways that control animal development and behaviors. Honors, Awards and Service to the Chinese Scientist Community 1988-91 Fellow of the Life Science Research Foundation 1991-1997 Lucille P. Markey Scholar in Biomedical Science 1992-1995 Basil O'Connor Scholar of March of Dimes Foundation 1993-1996 Searle Scholar 1997-current Selected and then renewed as a HHMI Investigator. 2011 Elected as Fellow of AAAS. 2000-2005 Members of Board Director, Vice President, CBI Society. 1996, 2004 Served as session chairs/speakers at SCBA meetings. 2010-current Ad hoc member of evaluation committees, China Academy of Science 2011-current Biology and Medicine Panel of the Research Grants Council of Hong Kong 1 Candidates for the Nomination Committee 5. NOMINATION: (VOTE FOR 6) Paul J. Chiao (University of Texas, Houston) _____ (Jan. 1, 2016 -‐ Dec. 31, 2017) Yingzi Yang (Harvard University) _____ Huilin Zhou (University of California, San Diego) _____ Qi-‐Jing Li (Duke University) _____ Wanjun Chen (NIDCR, Nat. Institutes of Health) _____ Julian J.-‐L. Chen (Arizona State University) _____ Xin Wei Wang (NCI, Nat. Institutes of Health) _____ PAUL J. CHIAO, Ph.D. Current Positions: Ashbel Smith Professor, Department of Molecular and Cellular Oncology The University of Texas M. D. Anderson Cancer Center University of Texas, Graduate School of Biomedical Sciences Education and Training: B.S., The University of Iowa, Iowa City, Iowa, 1986 Ph.D., The University of Texas Graduate School of Biomedical Sciences Postdoctoral Fellow, The Salk Institute for Biological Studies Previous Positions: 1995-2001 Assistant Professor, the University of Texas M.D. Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences, Houston, TX 2001-2007 Associate Professor, the University of Texas M.D. Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences, Houston, TX 2007-present Professor, the University of Texas M.D. Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences, Houston, TX 22011-present Ashbell Smith Professor, the University of Texas M.D. Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences, Houston, TX 09/2011-2014 Co-Director, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences/ M.D. Anderson Cancer Center and the University of Texas Health Science Center Research Interest: My laboratory has interests in regulation of gene expression and cell signaling in diseases. We first identified constitutive activation of NF-κB in pancreatic cancer and revealed the mechanisms of constitutive NF-κB activation, demonstrating NF-κB activation is required for mutant Kras to induce pancreatic cancer. Subsequently, we identified the function of NF-κB constitutive activation in Sjögren's Syndrome, common autoimmune disease. Our long term goal is not only to illuminate disease mechanisms, but also identify innovative drug targets for improving current treatments. Past services to SCBA Served as Treasure, Secretary, President-elected, President (2014) of SCBA Texas Chapter. Participated in organization of SCBA-Texas Chapter, The 27th, 28th, and 29th Annual Symposium Selected Honors and Awards and non-SCBA Services: 1981 Undergraduate Scholarship, University of Iowa, 1988 American Legion Auxiliary Fellowship for Predoctoral Research Award, Univ. of Texas, 1991 National Institutes of Health Postdoctoral Fellowship. 2011 Ashbel Smith Professorship, the University of Texas M.D. Anderson Cancer Center YINGZI YANG, PhD Current Position: Professor of Developmental Biology Harvard School of Dental Medicine Education and Training: BS, Biophysics, Fudan University, China, 1988 PhD, Molecular Biology, Weill Medical College of Cornell University and Sloan Kettering Cancer Institute, New York, 1996 Postdoctoral fellow, Harvard University, 1996-2000 Previous Positions: 2000- 2006 Investigator, National Human Genome Research Institute, NIH 2006- 2014 Senior Investigator, National Human Genome Research Institute, NIH Research Interest: My laboratory has a longstanding interest in understanding the functions and mechanisms of Wnt and Hedgehog signaling in development and disease. My lab has made major contributions in identifying the roles of Wnt and Hedgehog signaling in skeletal development and diseases. Our research has successfully bridged discoveries of fundamental mechanisms with characterization and treatment of diseases including severe birth defects, osteoporosis, osteoarthritis and heterotopic bone formation. Our studies have revealed fundamental mechanisms of Wnt and Hedgehog signal transduction and their critical roles in many aspects of embryonic morphogenesis and adult physiology. Awards and Honors 1995: Vincent du Vigneaud Award of Excellence from the Weill Medical College of Cornell University 1996-1999: Postdoctoral fellowship award from the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation. 2011: SCBA Young Investigator Award 2011: NIH APAO Outstanding Achievements and Merit Scholarship Award 2013: Keynote speaker at the NIH ceremony of Asian-American month Huilin Zhou, Ph.D. Current Position: Associate member, Ludwig Institute for Cancer Research Professor, Department of Cellular and Molecular Medicine, University of California, San Diego, CA Education and training: B.S. University of Science and Technology of China, Hefei, P.R. China, 1991 Ph.D. Stanford University, Palo Alto, CA, 1998 Postdoc fellow, Institute for Systems Biology and University of Washington, Seattle, WA, 2002 Research Interests: Our research program focuses on understanding the regulatory mechanisms of genome maintenance pathways including the DNA damage checkpoint and protein sumoylation. Genetic studies using the yeast Saccharomyces cerevisiae as a model organism have established a key role of DNA damage checkpoint kinases in suppressing gross chromosomal rearrangements (GCRs), a hallmark of human cancers. We have developed quantitative phospho-proteomics to identify and characterize substrates of DNA damage checkpoint kinases, as well as biochemical reconstitution of the activation of the kinase cascade. More recently, we have discovered that SUMO E3 ligases have a major role in suppressing duplication-mediated GCRs, which are driven by homeologous recombination, leading to chromosomal translocation events. We have further developed a novel quantitative mass spectrometry based assay to measure in vivo changes in protein sumoylation on a proteome-wide scale. Application of this approach allowed us to obtain a comprehensive picture of the enzymesubstrate relationship in the SUMO pathways, including SUMO E3 ligases that catalyze the attachment of SUMO to its substrates as well as SUMO isopeptidases that catalyze the removal of SUMO. These studies have revealed that the SUMO pathway has a broad role in chromosome biology, ranging from genome stability, gene silencing and chromosome segregation. We are further extending our findings using yeast as a model system to human cells and study the conservation of the underlying molecular mechanisms and their relevance to cancer etiology. Selected honors and previous service to SCBA: The NHGRI Genome Scholar Development and Faculty Transitional Award, 2002-2005. Participants/speakers of past SCBA meetings. QI-JING LI, Ph.D. Current Positions: Associate Professor of Immunology Department of Immunology, Program of Molecular Cancer Biology, Duke University Medical Center. Education and Training: B.S. in Biochemistry & Molecular Biology, Peking University, China, 1996 Ph.D. in Biochemistry & Molecular Biology, University of California, Riverside, CA, 2002 Postdoctoral Research Associate, Howard Hughes Medical Institute, Stanford University Medical School, CA, 2002-2008. Previous Positions: 2008-2015 Assistant Professor, Department of Immunology, Program of Molecular Cancer Biology, Duke University Medical Center. Research Interest: The major objective of my laboratory is to discover new immunoregulatory entities and to employ them to modulate the strength and pattern of T cell responses for clinical intervention, especially, for cancer immunotherapies. Currently, our major focus is microRNA (miRNA). Emerging evidence indicates that miRNAs are indispensable controlling elements of the adaptive immune system and can be used as an effective tool to manipulate a specific immune response. Despite challenges and complexities surrounding miRNA research, the biochemical characteristics of miRNAs bring several unique opportunities to basic and clinical medicine: I) In comparison to other forms of extracellular nucleic acids, miRNAs are exceptionally resistant to RNase degradation in body fluids. Also, PCR and sequencing based technologies for nucleic acid detection are far more sensitive and quantitative than those for protein detection. Therefore, circulating miRNAs represent a novel class of non-invasive biomarkers for various disease diagnosis and prognosis such as cancer. II) Unlike the lengthy and costly process of protein-based drug development, designing an oligonucleotide-based miRNA mimetic or antisense-based miRNA inhibitor for immune modulation is straightforward. We are actively pursuing novel immunoregulatory miRNAs for therapeutic targeting. III) Identifying miRNA targets is a way to discover novel proteins, or novel functions of known proteins in T cell biology. In contrast to siRNA-based methods that normally employ hundreds of thousands of hits, the limited number makes “reverse epigenetic screening” of a miRNA expressing/targeting library much more feasible. In addition, complementary paring between the miRNAs seed region and target mRNA sequence is required for most miRNAs to execute gene regulation. Therefore, my laboratory employs miRNAs as tools for discovery. Selected Honor and Awards and non-SCBA services: 2003-2006 2009-2012 2010-2012 2010-2014 201220122015- Helen Hay Whitney Foundation Postdoctoral Research Fellowship Whitehead Scholarship, The Whitehead Family Foundation The American Diabetes Association Junior Faculty Award The American Cancer Society Research Scholarship External reviewer for Portuguese Foundation for Science and Technology (FCT) Reviewer for the Cellular and Molecular Immunology-B study section, Center for Scientific Review, NIH, USA. Reviewer for the Immunology and Microbiology Panel, Human Exploration Research Opportunities, National Aeronautics and Space Administration (NASA), USA. WANJUN CHEN, M.D. Current Positions: Senior Investigator Chief, Mucosal Immunology Section, OPCB, NIDCR, NIH Education and Training: M.D., Qingdao Medical College, China, 1984 M.S. Immunology, Shandong Medical University Shandong Academy of Medical Sciences, China, 1987 Postdoctoral fellow, Harvard Medical School, MA, 1992-1996 Previous Positions: 1997-2003, Senior Staff Fellow, Cellular Immunology Section, OIIB, NIDCR, NIH 2004-2010, Tenure-track Investigator, Chief, Mucosal Immunology Unit, OIIB, NIDCR, NIH 2011-present, Senior Investigator (tenured), Chief, Mucosal Immunology Section OPCB, NIDCR, NIH Research Interest: My laboratory is elucidating mechanisms of TGF-β regulation of T-cell immunity and tolerance with focus on regulatory T cells (Tregs), and manipulating T-cell immunity versus tolerance in animal models to understand the pathogenesis of autoimmunity and inflammation, cancer and infectious diseases and to develop potential therapies for relevant human diseases. We discovered TGF-β induces Foxp3 in naïve CD4+ T cells and converts them into Foxp3+ regulatory T cells. Past and current services to SCBA: Session Chair, 13rd International SCBA Conference, Guangzhou, China, 2011 Keynote Speaker, Annual Meeting of The Texas Chapter of SCBA, Houston, 2011 Chair, SCBA Joint Session, Chinese Biopharmaceutical Association USA (CBA) Annual Meeting, Rockville, MD, 2014 Co-Chair, SCBA DC-Baltimore Chapter Annual Scientific Symposium, Baltimore, 2015 Session Co-Chair, The 15th International SCBA Symposium, Taipei, 2015 President, SCBA Washington DC-Baltimore Chapter, 2015 Selected Honors and Awards and non-SCBA services: Invited Speaker, NIH Director’s Seminar Series, NIH, 2009 Co-organizer, Keystone Symposium, TGF-β in Immune Responses, Utah, 2011 The Wang Ying-Lai Memorial Lecture, Houston, 2011 Scientific Achievement Award, NIH Asian and Pacific Islander American Organization, NIH, 2013 Chair, NIH Stadtman Tenure-track Investigator Search Immunology Committee, NIH 2011-12 JULIAN J.-L. CHEN, Ph.D. Current Position Associate Professor Department of Chemistry and Biochemistry Arizona State University, Tempe Education and Training B.S., Biology, National Cheng-Kung University, Taiwan, 1991 Ph.D., MCDB, Indiana University, Bloomington, IN, 1997 Postdoctoral Fellow, Johns Hopkins University School of Medicine, 1998-2004 Previous Positions 1991 –1992 Research Technician Institute of Molecular Biology, Academia Sinica, Taiwan 2003 –2004 Research Associate Department of Molecular Biology and Genetics Johns Hopkins University, School of Medicine 2004 –2010 Assistant Professor Department of Chemistry & Biochemistry Arizona State University, Tempe, Arizona 2004 –2010 Assistant Professor (Joint Appointment) School of Life Sciences, Cellular & Molecular Biosciences Division Arizona State University, Tempe, Arizona Research Interest Telomerase is a highly specialized reverse transcriptase that adds simple DNA repeats onto linear chromosome ends to maintain genomic integrity and sustain cellular immortality in eukaryotes. My research aims to understand the inner workings of telomerase and to develop telomerase-targeting therapeutics for aging, cancer and telomere-mediated diseases. My research employs interdisciplinary approaches spanning biochemistry, bioinformatics, structural biology and molecular genetics. Honors and Awards 2000-2003 Fellow of The Leukemia & Lymphoma Society 2005 MARC Travel Award 2007-2012 NSF Faculty Early Career Development (CAREER) Award Professional Service Panel Reviewer for Grant Funding Agency: NIH Study Section-Molecular Genetic - MGA (Regular Member, 2012-present) Ad hoc Reviewer for Grant Funding Agencies: National Institutes of Health (NIH) Study Section MGA (2011), National Science Foundation (NSF) (2006, 2010, 2012), Maryland Technology Development Corporation (TEDCO) (2011), Austrian Science Fund (FWF) (2010), US-Israel Binational Science Foundation (2006) Editorial Board Member of Scientific Journals: Journal of Biological Chemistry (2013 - present), Frontiers in Genetics – Non-coding RNA (2010 - present) Meeting Session Chair: The 2013 Telomeres and Telomerase Meeting at Cold Spring Harbor Laboratory, NY Selected Publications Qi, X., D.R. Rand, J.D. Podlevsky, Y. Li, A. Mosig, P.F. Stadler and J.J.-L. Chen (2015) Prevalent and distinct spliceosomal 3ʹ′-end processing mechanisms for fungal telomerase RNA. Nature Communications 6, 6105. Brown, A.F., J.D. Podlevsky, X. Qi, Y. Chen, M. Xie and J.J.-L. Chen (2014) A self-regulating template in human telomerase. Proc. Natl. Acad. Sci. U.S.A. 111(31): 11311-11316. [From the Cover] Huang, J., A.F. Brown, J. Wu, J. Xue, C.J. Bley, D.P. Rand, L. Wu, R. Zhang, J.J.-L. Chen* and M. Lei* (2014) Structural basis for protein-RNA recognition in telomerase. Nature Structural and Molecular Biology 21: 507-512. Qi, X., M. Xie, A.F. Brown, C.J. Bley, J.D. Podlevsky and J.J.-L. Chen (2012) RNA/DNA hybrid binding affinity determines telomerase template translocation efficiency. EMBO J. 31: 150-161. Bley, C.J., X. Qi, D.P. Rand, C.R. Borges, R.W. Nelson and J.J.-L. Chen (2011) RNA-protein binding interface in the telomerase ribonucleoprotein. Proc. Natl. Acad. Sci. U.S.A. 108(51): 20333-20338. Xin Wei Wang, Ph.D. Current Positions: Senior Investigator and Deputy Chief, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute Education and Training: B.S., Shanghai First Medical College, Shanghai, China, 1982 M.S., Chinese Academy of Sciences, Shanghai, China, 1984 Ph.D., New York University, New York, New York, 1991 Postdoc Fellowship, Roche Institute of Molecular Biology, Nutley, New Jersey, 1992 Previous Positions: Senior Staff, National Cancer Institute, 1995-97 Chief, Liver Carcinogenesis Unit, National Cancer Institute, 1998-2005 Adjunct Associate Professor, University of Maryland Cancer Center, 2002Chief, Liver Carcinogenesis Section, National Cancer Institute, 2005Research Interests: Want’s lab is interested in studying biochemical pathways related to human cancer with a special focus on cancer functional genomics. Primary liver cancer is the second most deadly cancer in men and fifth most prevalent cancer worldwide. It remains as the most difficult-to-treat malignancies, with a 5-year survival rate lingering at 15% in the United States. His lab is exploring molecular mechanisms to explain how cancer cells initiate and metastasize, and to develop clinically relevant biomarkers and molecular genetic-based therapeutics for liver cancer. Currently, his lab is centered on two main complementary research projects with an objective to change the current status quo. Project one is to dissect molecular heterogeneity of liver cancer to improve outcome among diverse populations. Project two is to apply integrated genomics to identify drivers of human liver cancers. Previous Services to SCBA: SCBA life-time member since 2002 SCBA Baltimore-DC Chapter Treasurer since 2009 Selected Honors and Awards, and Services: Federal Technology Transfer Awards (1998-2012) Board of Directors, International Society of Gastroenterological Carcinogenesis, 2003-09 Natural Sciences Award (first place), The Ministry of Education of China, 2008 NCI Outstanding Mentor Award (Mentor of Merit), 2009 NIH APAO Outstanding Scientific Achievement Award, 2010 The SCBA Outstanding Leadership and Service Award, 2011 NIH Director’s Award, 2013, NIH Merit Award, 2009, 2013 Governing Board, International Liver Cancer Association, 2013Blue Faery Award for Excellence in Liver Cancer Research, 2014 Candidates for the Membership Committee 6. MEMBERSHIP: (VOTE FOR 6) Yi Li (Baylor College of Medicine) _____ (Jan. 1, 2016 -‐ Dec. 31, 2017) Xuhang Li (Johns Hopkins University) _____ Wei Gu (Columbia University) _____ Zhibin Chen (University of Miami) _____ Yingming Zhao (University of Chicago) _____ Deyu Fang (Northwestern University) _____ Yixian Zheng (Carnegie Institution of Science) _____ Yue Xiong (University of North Carolina) _____ YI LI, Ph.D. Current Position: Associate Professor, Lester & Sue Smith Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine Education and Training: B.S., Yangzhou University, 1984 M.S, Yangzhou University, 1987 Ph.D. Michigan State University, 1996 Postdoctoral Fellow, Michigan State University, 1996-1997; NCI, 19972000; MSKCC, 2000-2002 Previous Positions: 12/2002 – 3/2011 Assistant Professor, Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX. 5/2005 – present Associate Member, Stem Cells and Regenerative Medicine, Baylor College of Medicine. 12/2011 – present Adjunct Professor, The University of Texas Health Science Center at Houston 5/2011 – present Faculty Associate, Huffington Center on Aging, Baylor College of Medicine. 4/2011 – present Associate Professor, Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX. Research Interest: The Li laboratory studies the molecular and cellular mechanisms of breast cancer initiation and evolution and translates this knowledge into breast cancer prevention and treatment in both preclinical models and a clinical setting. The Li laboratory pioneered the use of the RCAS-TVA avian retroviral system for closely mimicking human breast cancer initiation in mice. The Li laboratory use this method and genetically engineered mouse models as well as human cell lines and patient tissues to study the fundamental questions in breast cancer initiation, progression, and metastasis as well as prevention. The Li laboratory also studies how pregnancy, diabetes, and antipsychotic drugs impact breast cancer risk as well as breast cancer stem cells. The main signaling pathways that are studied in the Li laboratory include Wnt, LGR4, ErbB2, and JAK2-STAT5. Previous Service to SCBA: 2008-2009 Treasurer, SCBA-Texas Chapter, 2011-2012 President-Elect, SCBA-Texas Chapter, 2012-2013 President, SCBA-Texas Chapter, 2013 Chair, Annual symposium of SCBA-TX 2013 Co-Chair, The Second Biennial International Symposium of SCBA-TX: Jiangsu Biomedical Symposium on Cancers and Other Human Diseases: From Mechanisms to Bedside. Nanjing, China. 2012 2013-2015 Member of the SCBA membership committee XUHANG LI, PhD Current Position: Assistant professor of medicine Department of Medicine, GI Division Johns Hopkins University School of Medicine Education and Training: Bachelor of Science: Department of Biology, Shandong University, China, 1983, Master of Science: Institute of Botany, Chinese Academy of Science, Beijing, China, 1988, Ph.D.: Department of Cell Biology and Molecular Genetics, University of Maryland College Park, Maryland, 1998, Post-doctoral fellow: Laboratory of Molecular Biology, National Cancer Institute, National Institute of Health, Bethesda, Maryland, 1998 Department of Medicine, Johns Hopkins University School of Medicine, 1999-2004 Previous Positions 1988-1990 Faculty research associate, Institute of Botany, Chinese Academy of Science, Beijing China 1990-1992 Research associate, University of Maryland, College Park, Maryland 2002 Instructor, John Hopkins University, School of Medicine, Baltimore, Maryland 2006 Assistant professor, John Hopkins University, School of Medicine, Baltimore, Maryland RESEARCH ACTIVITIES My laboratory in the GI Division/Department of Medicine conducts vigorous research in two major areas of GI diseases: inflammatory bowel disease (IBD) and diarrhea. We have extensive expertise and experience in protein biochemistry and proteomics, as well as in applying various biochemical, molecular and proteomic approaches in studying IBD and diarrhea associated with disregulation of intestinal transporters. Specifically, our research projects include: 1). Biomarker Discovery and Development for Diagnosis and Prognosis of Inflammatory Bowel Disease (IBD) and Other Autoimmune Diseases. Through various state-of-art technologies, including high-throughput protein chip technology and multiplex ELISA, we have recently identified multiple interesting and potentially high-value protein/antibody candidates that may be developed as diagnostic and or prognostic biomarkers for IBD. Biomarker of other autoimmune disorders, such as autoimmune liver diseases as well common GI disorders such as irritable bowel syndrome (IBS) are also under our investigation. 2). Exploring Molecular Pathogenesis and Developing Novel Therapeutics of Inflammatory Bowel Disease (IBD). Using various biochemical and molecular technologies, including quantitative proteomics, flow cytometry, gene-profiling, we are identifying novel signaling pathways that are potentially involved in pathogenesis of IBD or diarrhea. Research involves both human and multiple animal models of IBD. Our lab maintains more than eight different specific gene-knockout mouse lines that are used as model systems for molecular dissecting pathogenic mechanisms and developing new therapeutic of IBD. Past service to SCBA: - Live-time membership - Organizing happy hours, dinner and picnic, together with Dr. Aiping Zhao for SCBA activity and membership drives Honors and Awards 1997 Elected to the Honor Society of PHI KAPPA PHI 1997 Graduate School Goldhaber Award, University of Maryland at College Park 2002-2007 The NIH Research Scientist Career Development Award 2005 Scientist of the Year Award, Department of Medicine/GI Division, Johns Hopkins university School of Medicine 2007Visiting Research Professorship, Shanghai Jiaotong University School of Medicine 2012Visiting professorship, Wuhan University and PLA Military Hospital of Beijing Wei Gu, Ph.D. Current Positions: Abraham and Mildred Goldstein Professor endowed chair Professor and Vice-Chairman for Cancer Research at the department of Pathology and Cell biology and Institute for Cancer genetics in Columbia University, New York, NY, USA. Education and Training: B.S. Peking University, Beijing, China, 1986 Ph.D. Columbia University, New York, USA, 1995 Postdoctoral Fellow, Rockefeller University, New York, 1995-1998 Previous Positions: 1999 -2004 Assistant Professor (Tenure-track), Columbia University Medical Center, New York, NY 1999 -Present Principal Investigator/Member, Columbia University Herbert Irvine Cancer Center 2004 -2006 Associate Professor (Tenured) 2007-Present Full Professor at Columbia University Medical Center 2013-Present Abraham and Mildred Goldstein Endowed Chair, Columbia University 2013-Present Vice-Chairman for Cancer Research at the department of Pathology and Cell Biology, Columbia University, New York, USA Research Interests: My laboratory is recognized for the pioneering contributions to p53 modifications in tumor suppression. First, we discovered that p53 activity is controlled in large part by acetylation and deacetylation. My lab has established that acetylation of specific p53 residues is required for its transcriptional function and acts as the primary signal to differentially induce its canonical functions in apoptosis, cell growth arrest and senescence. Second, my lab has identified “dynamic ubiquitination” (polyubiquitination, monoubiquitination and deubiquitination) as the major mechanism by which the stability and subcellular localization of p53 protein are determined. Notably, several of our findings have had important implications well beyond p53 biology. For example, the studies of p53 acetylation laid the foundation for the current view that reversible acetylation is a general mechanism for regulation of non-histone proteins. Overall, my laboratory plays a leading role in the field of mechanistic studies of p53-mediated tumor suppression and our studies have uncovered several new strategies to target the tumor suppression pathway therapeutically. Past services to SCBA Session Chair, Scientific Program Committee, 11th SCBA International Symposium. 2006 Selected Honors and Awards 1995 Columbia University Dean’s Award for Outstanding Research Achievement. 1995-1998 Life Science Research Foundation Fellowship for Advanced Cancer Studies. 1999-2000 America Cancer Society Award 2000-2002 Avon Scholar Award 2001-2005 Irma T. Hirschl Trust Award 2001-2006 Leukemia & Lymphoma Society Scholar 2006 The Stohlman Scholar 2007-2011 Ellison Medical Foundation Senior Scholar in Aging ZHIBIN CHEN, M.D., Ph.D. Current Positions: Associate Professor, Department of Microbiology and Immunology, Miller School of Medicine Member, Sylvester Comprehensive Cancer Center University of Miami, Miami, FL Education and Training: M.D., Luzhou Medical College, China, 1988 M.S., Immunology, Tianjin Medical College, China, 1991. Ph.D., Immunology, Duke University, NC, 2000. Postdoctoral fellow. Harvard Medical School, MA, 2001-2006 Previous Positions: 1991-1994 Assistant Investigator, Chengdu Institute of Biological Products, Ministry of Public Health, Chengdu, Sichuan, China 2001-2006 Research Fellow, Joslin Diabetes Center, Harvard Medical School, Boston, MA 2007-2013 Assistant Professor, Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 2007-present Affiliated Member, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 2009-present Member, the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL Research Interest: My search program mainly focuses on immune tolerance mechanisms, using murine models of human diseases, in synergy with clinical studies. My group discovered bystander tissue cell growth as a mechanism of tissue regeneration at the front of immune damage. We also tackle on a basic puzzle in immunology, how the clonal selection theory fits at the intestinal interface where “friendly” bacteria largely outnumber the eukaryotic cells of a mammalian body. We discovered cross-differentiation from CD8 lineage to MHC class-I-restricted CD4+Foxp3+ regulatory T cells and found evidence for a “selfless” mode of immune tolerance induction. Selected Honors and Awards, and non-SCBA services: 1999-present Regular Member, American Association of Immunologists 2001 Postdoctoral Fellowship, Juvenile Diabetes Research Foundation International. 2004 NRSA Fellow, Postdoctoral Training Program in AIDS Research (DFCI/NIH) 2014 NIDDK/NIH Review Committee. ZDK1 GRB-S (O4). Consortium on Beta-cell Death and Survival (HIRN-CDBS) (UC4). 2015 NIDDK/NIH Review Committee. GRB-J M6. Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24). 2015 NIDDK/NIH Review Committee. Consortium on Beta-cell Death and Survival (HIRN-CBDS) (UC4) (HIRN-CTAR) (UC4). Yingming Zhao, Ph.D. Current Position: Professor, Ben May Department for Cancer Research The University of Chicago Education: B.S., East China University of Science and Technology, Shanghai, China, 1984 Ph.D., The Rockefeller University, 1997 Previous Positions: 1998-2000 Assistant professor, Department of Human Genetics, Mount Sinai School of Medicine 2000-2005 Assistant Professor, Department of Biochemistry, UT Southwestern Medical Center 2005-2008 Associate Professor, Department of Biochemistry, UT Southwestern Medical Center 2008-2011 Associate Professor, Ben May Department for Cancer Research, The University of Chicago 2011-present Professor, Ben May Department for Cancer Research, The University of Chicago Research Interest: The Zhao Lab’s main research interests lie in developing and applying MS-based proteomics technologies to discovery of cellular pathways. He also use an integrated approach, involving proteomics, biochemistry, molecular biology, and cell biology to decode protein post-translational modification (PTM) networks that have implications for human health and are not amenable to conventional techniques. His lab recently discovered seven types of new lysine acylation pathways: propionylation, butyrylation, crotonylation, malonylation, succinylation, glutarylation, and 2-hydroxyisobutyrylation. They identified more than 200 new histone marks, which doubles the tally of the previous known histone marks discovered during the first forty years of chromatin biology. They revealed numerous enzymes for the new PTM pathways. Specifically, his lab is the first who demonstrates acetylation-independent functions of deacetylases, including Sirt5 as a desuccinylase, demalonylase, and deglutarylase. His laboratory demonstrates that the new PTM pathways have critical roles in epigenetic regulation and cellular metabolism. And these pathways can explain cellular dysfunctions associated with diverse inborn metabolic diseases, therefore offering new avenues for therapeutic intervention. Deyu Fang, Ph.D. Current Positions: Associate Professor Department of Pathology, Northwestern University Feinberg School of Medicine, Education and training: B.S. Weifang Medical College, China, 1991 M.S. Dalian Medical University, China, 1994 Ph.D. Gunma University School of Medicine, Japan, 2000. Postdoctoral fellow, La Jolla Institute for Allergy and Immunology, San Diego, CA, 2003 Previous Positions: 2003-2005, Instructor (Research Investigator), Department of Biochemistry, University of Michigan School of Medicine. 2005-2009, Assistant Professor, Department of Microbiology and Immunology University Of Missouri School of Medicine 2009-present, Associate Professor, Department of Pathology Northwestern University Feinberg School of Medicine Research Interests: My laboratory is interested in understanding the molecular mechanisms in immune regulation and autoimmune diseases in mouse and human. In particular we are focusing on studying the posttranslational protein modifications, including ubiquitination and acetylation in regulating the development, activation and differentiation of immune cells during infection and inflammatory response. Yixian Zheng, Ph.D. Current Position: Investigator, Dept. of Embryology, Carnegie Institution for Science, Baltimore, MD Adjunct Professor, Dept. of Biology, Johns Hopkins University (JHU) Education and Training 09/1980 – 07/1984 B.S. in Genetics, Sichuan University, Sichuan, China 01/1987 – 09/1992 Ph.D, Ohio State University, Columbus, Ohio 10/1992 – 08/1996 Postdoctoral Fellow, University of California, San Francisco Previous Positions: 09/1984 – 11/1986 Lecturer, Southwestern Agricultural University, Sichuan, China 09/1996 – Present Investigator, Department of Embryology Carnegie Institution for Science, Baltimore, MD 1996 – 2007 Adjunct Assistant, Associate Professor, Professor Dept. of Biology, JHU 2000 – 2012 HHMI Investigator, Howard Hughes Medical Institute Research Interest: My lab has a long-standing interest in cell division. In recent years, the findings we have made have broadened our research scope to include the study of stem cells, genome organization, and lineage specification using animal models. We have three research areas. 1. The mechanism of cell division. 2. The mechanism of genome organization in development, homeostasis, and aging. 3. The influence of cell morphogenesis on cell fate decisions. We use a wide range of tools and systems, including genetics in model organisms, cell culture, biochemistry, proteomics, genomics in our research. Services to SCBA: Chair and organizer: the First Baltimore-DC local chapter symposium, Baltimore, MA Selected Honors and Awards: 1997 – 2001: PEW Scholar Award (Awarded by PEW Charitable Trusts) 1999: Women in Cell Biology Award (Junior) (American Society for Cell Biology) 07/2007: Keynote Speaker, Gordon Conference - Motile & Contractile Systems 09/2008: National Associate of the National Research Council, the National Academies of Sciences 08/2012 – 08/2016: Senior Scholar in Aging, Ellison Medical Foundation 1 Yue Xiong, Ph.D. Current positions: William R. Kenan Jr. Professor of Biochemistry and Biophysics Leader, Cancer Cell Biology Program, Lineberger Cancer Center University of North Carolina at Chapel Hill Education and training B.S., Biology, Fudan University, Shanghai, China, 1982 Ph.D. Molecular Biology, University of Rochester, 1989 Postdoctoral: Cold Spring Harbor Laboratory, 1990 - 1993 Previous positions 1993 – 1999: Assistant Professor 1999 – 2003: Associate Professor (tenured) 2003 – 2005: Professor 1993 –present: member, Lineberger Comprehensive Cancer Center 1993 – present: member, Program in Molecular Biology & Biotechnology University of North Carolina at Chapel Hill Research interests I have long-standing interest in understanding the mechanisms of cancer development and have been focusing on three areas. (1) The function and regulation of CDK inhibitor genes. (2) The cell cycle control and p53 signaling by the ubiquitin pathway. (3) Cancer metabolism. Selected honors and awards 1995 1995 1999 1999 1999 2006 2011 2012 ACS Junior Faculty Research Award Pew Scholar in Biomedical Sciences AACR-G. Elion Cancer Research Award Department of Defense Breast Cancer Research Career Development Award UNC Hettleman Award for Scholarly Achievement American Lung Association Diane Emdin Sachs Lung Cancer Award UNC Battle Distinguished Cancer Research Award Elected fellow, American Association for the Advancement of Science Participation in SCBA Life-time member since 1995 Speakers and session chairs at multiple SCBA meetings 1